SCHEMBL3392547

SCHEMBL3392547

CC1CCC(O[Si](C)(C)C)CC1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.33
CYP19A1 P11511 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8788188 0.88
SCHEMBL7941245 0.77 ACHE (0.30)
SCHEMBL18137684 0.76
SCHEMBL19951089 0.76
SCHEMBL8742177 0.76
SCHEMBL10203452 0.75 PPM1D (0.31)
SCHEMBL16569783 0.74 CA1 (0.33)
SCHEMBL301584 0.74 CA1 (0.33)
SCHEMBL938204 0.72 LRRK2 (0.33)
SCHEMBL8753991 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368013-B1 CYCLOHEXENONE DERIVATIVE FOR TREATING DIABETIC NEUROPATHY MEIJI DAIRIES CORP (JP) 2010-12-22 EP disclosed
US-7838565-B2 Use of cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications MEIJI DAIRIES CORPORATION (JP) 2010-11-23 US disclosed
EP-1368014-B1 USE OF CYCLOHEXENONE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF DYSURIA MEIJI DAIRIES CORP (JP) 2006-11-22 EP disclosed
US-6906107-B2 Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria MEIJI DAIRIES CORPORATION (JP) 2005-06-14 US disclosed
US-20040132829-A1 Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2004-07-08 US disclosed
US-20040102527-A1 Use of cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2004-05-27 US disclosed
EP-1368014-A1 USE OF CYCLOHEXENONE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF DYSURIA Meiji Dairies Corporation (JP) 2003-12-10 EP disclosed
WO-2002066024-A1 USE OF CYCLOHEXENONE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF DYSURIA MEIJI DAIRIES CORPORATION (JP) 2002-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132829-A1 Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria ADH1A, ADH1C, NDUFB7 ESR2 1490/4885CYP19A1 684/4885
US-20040102527-A1 Use of cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications GPR119, CYC1, CYP11B1 ESR2 1373/4885CYP19A1 609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.